We sought to investigate the usefulness of the adeno-associated virus 2 (AAV)-based vectors to suppress the excess production of the human cx-globin gene product towards developing a treatment modality for B-thalassemia since accumulation of free c~-globin reduces the lifespan of red blood cells in these patients. We constructed recombinant AAV virions containing the human ~x-globin gene sequences in antisense orientation driven by the herpesvirus thymidine kinase (TK) promoter, the SV40 early gene promoter, and the human cx-globin gene promoter, respectively, as well as a bacterial gene for resistance to neomycin (neo ~) as a selectable marker. These recombinant virions were used to infect a human erythroleukemia cell line (K562) that expresses high levels of c~-globin mRNA. Clonal populations of neo p" cells were obtained after selection with the drug G418, a neomycin analogue. Total genomic DNA samples isolated from these cells were analyzed on Southern blots to document stable integration of the transduced neo and o~-globin genes. Total cellular RNA samples isolated from mock-infected and recombinant virus-infected cultures were also analyzed by Northern blots. Whereas the TK promoter-driven antisense cx-globin sequences showed no inhibition of expression of the endogenous ol-globin gene, the SV40 promoter and the oe-globin gene promoter-driven antisense ot-globin sequences suppressed the expression of this constitutively over-expressed gene by approximately 29 and 91%, respectively, at the transcriptional level. These studies suggest the feasibility of utilizing the AAV-based antisense gene transfer approach in the potential treatment of t3-thalassemia.
We sought to investigate the usefulness of the adeno-associated virus 2 (AAV)-based vectors to suppress the excess production of the human cx-globin gene product towards developing a treatment modality for B-thalassemia since accumulation of free c~-globin reduces the lifespan of red blood cells in these patients. We constructed recombinant AAV virions containing the human ~x-globin gene sequences in antisense orientation driven by the herpesvirus thymidine kinase (TK) promoter, the SV40 early gene promoter, and the human cx-globin gene promoter, respectively, as well as a bacterial gene for resistance to neomycin (neo ~) as a selectable marker. These recombinant virions were used to infect a human erythroleukemia cell line (K562) that expresses high levels of c~-globin mRNA. Clonal populations of neo p" cells were obtained after selection with the drug G418, a neomycin analogue. Total genomic DNA samples isolated from these cells were analyzed on Southern blots to document stable integration of the transduced neo and o~-globin genes. Total cellular RNA samples isolated from mock-infected and recombinant virus-infected cultures were also analyzed by Northern blots. Whereas the TK promoter-driven antisense cx-globin sequences showed no inhibition of expression of the endogenous ol-globin gene, the SV40 promoter and the oe-globin gene promoter-driven antisense ot-globin sequences suppressed the expression of this constitutively over-expressed gene by approximately 29 and 91%, respectively, at the transcriptional level. These studies suggest the feasibility of utilizing the AAV-based antisense gene transfer approach in the potential treatment of t3-thalassemia. deno-associated virus 2 (AAV) is a nonpathogenic human parvovirus that requires coinfection with either adenovirus, herpesvirus, or vaccinia virus for its optimal growth and replication (1). In the absence of a helper virus, the AAV genome integrates into chromosomal DNA in a site-specific manner on chromosome 19 in human cells (2) (3) (4) . The AAV genome is a single-stranded DNA containing identical inverted terminal repeats (ITRs) that act as the sole c/s-acting elements for the viral DNA replication (5-7). Several AAVbased recombinant virions have been constructed by replacing the entire viral genome with a foreign DNA between the two ITRs, and have been shown to be functionally active upon infection of a variety of established cell lines and primary ceU cultures in vitro (8) (9) (10) .
The nonpathogenic nature of AAV, coupled with the remarkable site specificity of integration, has added to its desirable features as a vector for gene therapy (8) (9) (10) (11) (12) (13) ). In the current study, we investigated the potential application of the AAV-based vector system as a treatment modality for /3-thalassemia, a heritable disorder characterized by defective synthesis of 3-globin chains. In the homozygous condition, 13-thalassemia is also characterized by accumulation of excessive free cx-globin chains which results in premature death of erythroid progenitor cells before they reach the reticulocyte stage (14) . This imbalanced production of globin chains results in red cell damage shortening their lifespan. A mechanism that could control the excess production of free ~x-globin chains would be expected to largely benefit in the amelioration of clinical severity of this disease.
The strategy we employed was based on suppression of the augmented ot-globin levels at the transcriptional stage through the production of antisense ol-globin RNA sequences mediated by AAV. We observed significant inhibition of expression of the endogenous oe-globin gene in K562 cells upon infection with recombinant AAV virions harboring the antisense human o~-globin DNA sequences driven either by the SV40 early promoter or the human o~-globin gene promoter. We suggest that the AAV-based vector system may prove useful in the potential gene therapy of human hemoglobinopathies in general, and 13-thalassemia in particular.
Materials and Methods
Plasmids, Viruses, and Cells. Recombinant clones of AAV plasmids have been described (15, 16) , and were obtained from Dr. K. J. Samulski (University of North Carolina, Chapel Hill, NC). Two recombinant AAV plasmids containing the neo R gene driven by either the SV40 promoter (pAAV-Neo), or the TK promoter (pWP-19), have also been described (17, 18) . A recombinant plasmid containing the genomic copy of human c~-globin gene (pTRZ1) was kindly provided by Dr. George Stamatoyannopoulos (University of Washington, Seattle, WA). A recombinant plasmid containing the SV40 promoter-driven chloramphenicol acetyl transferase (CAT) gene (pCAT-control) was purchased from Promega Biotech (Madison, WI). Human adeno-associated virus 2 (AAV-2H), and human adenovirus 2 (Ad2) viral stocks were provided, respectively, by Dr. K. I. Betas, (Cornell University Medical College, New York) and Dr. K. H. Fife (Indiana University School of Medicine, Indianapolis, IN), and were grown and maintained as previously described (19) (20) (21) . The human erythroleukemia cell line, K562, was obtained from the American Type Culture Collection (R.ockville, MD), and maintained in IMDM supplemented with 10% FBS.
Construction of Recombinant Plasmids and Viruses. The overall strategy for the construction of the three different recombinant AAV plasmids is illustrated in Fig. 1 . Plasmid pSP-2, containing the thymidine kinase (TK) promoter-driven human o~-globin gene sequence in antisense orientation ( Fig. 1 A) was constructed as follows: the c~-globin fragment was isolated from plasmid pTRZ1 using restriction enzymes NcoI and PvulI, and cloned between BgllI and SmaI sites of plasmid pTK-Neo after treatment with Pollk by the standard methods described in Sambrook et al. (22) to yield a plasmid, designated pSP-1, which also contained the TK polyadenylation (poly A) signal sequence. A DNA fragment containing the TK promoter-driven antisense c~-globin gene was excised from plasmid pSP-1 using EcoRI and HindlII and cloned at the EcoRI site of plasmid pAAV-Neo after treatment with Pollk to yield a plasmid, designated pSP-2. This plasmid contains the antisense c~-globin sequences driven by the TK promoter, and the neo R gene driven by the SV40 promoter. Plasmid pSP-12, containing the SV-40 promoter-driven or gene in antisense orientation, and the TK promoter-driven neo R gene (Fig. 1 B) , was constructed by replacing the CAT coding sequences in pCAT-control by the c~-globin sequences in antisense orientation to generate a plasmid, designated pSP-7, in which the SV40 poly A signal was retained at the 3' end. Further, the SV40 promoter-driven antisense c~-globin sequences were isolated from pSP-7 using EcoRI and XbaI, and cloned at the BamHI site of pWP-19 after treatment with PolIk. The resulting plasmid, designated pSP-12, contains SV40 promoterdriven antisense c~-globin sequences and the TK promoter-driven neo ~" gene sequences flanked by the AAV-ITRs. Plasmid pSP-17 was constructed with the human c~-globin gene promoter-driven antisense c~-globin sequences, and the TK promoter-driven neo ~ (Fig. 1 C) . Plasmid pSP-o~, containing the entire coding region as well as the promoter region of the human c~-globin sequences, was digested with NcoI and HindIII to remove the coding region of the o~-globin coding sequence, and a 1.0-kh DNA fragment isolated from Hinfl-digestion of plasmid pTRZ1 that contained the c~-globin coding region was cloned in antisense orientation after treatment with PolIk to yield a plasmid, designated pSP-15. The c~-globin poly A sequence was retained in pSP-15. The c~-globin promoter-driven antisense c~-globin sequences were further cloned Construction of antisense human ot-globin gene-containing recombinant AAV plasmids and virions. The overall strategy for construction of the recombinant AAV genomes containing antisense c~-globin sequences driven by the TK promoter (vTKp-globin-~; A), the SV40 promoter (vSV40p-globin-ot; B), and the c~-globin promoter (votp-globin-c~; C), is described under Materials and Methods.
at the BamHI site of plasmid pWP-19 after treatment with PoRk to generate a recombinant plasmid, designated pSP-17.
All three recombinant AAV genomes were rescued from their respective phsmids, packaged into mature AAV virions, as previously described (23) , and designated vTKp-globin-o~, vSV40p-globin-~, and vo~p-globin-c~, respectively. The viral titers were determined on quantitative DNA slot blots as p~viously described (24) .
Recombinant Virus Infections and Selection of neo ~ Colonies. K562 cells were infected with the recombinant viruses at a multiplicity of infection (m.o.i.) of I in 0.5 ml of IMDM. Infection was allowed to proceed at 37~ for 2 h after which the cells were plated in 10 ml IMDM supplemented with 10% FBS and grown at 37~ 48 h post-infection (p.i.), the drug G418 was added to the medium at a final active concentration of 400/~g/ml, and the cultures were maintained for at least 2 wk before selecting the he0 ~ clonal cell populations. The neo ~ colonies were propagated in IMDM supplemented with 10% FBS and 400/~g/ml G418.
Southern Blot Analysis for Viral Integration. Total genomic DNA samples isohted from mock-infected, or the recombinant virusinfected, neo ~ clones of K562 cells were subjected to digestion with a variety of restriction endonudeases and analyzed on Southern blots as previously described (25) . 32P-hbeled ot-globin-and neomycin-specific DNA probes were used to hybridize to the filters and autoradiographed.
Northern Blot Analysis of Expression of the Endogenous ot-Globin
Gen~ Total cellular RNA was isohted from the recombinant virusinfected he0 ~ colonies of K562 cells as well as from mock-infected K562 ceUs following standard methods (26) . Northern blots of equivalent amounts of different RNA samples were probed with 3zp-hbeled c~-globin-, /~-actin-, and neomycin-specific DNA probes. The levels of expression of the endogenous c~-globin RNAs were quantitated by scanning the autoradiograms using a video densitometer (model620; Bio-Rad Laboratories, Richmond, CA). 3, 7, 11) , and vo~p-globin-ot (lanes 4, 8, 12), were cleaved with the indicated restriction endonucleases and analyzed on Southern blots using a neo-spedfic DNA probe as described under Materials and Methods. HindIII-cleaved PM2 DNA fragments were codectrophoresed as size-markers.
Results
Successful Transduction of K562 Cells with the Recombinant AAV Vectors. The recombinant AAV genomes we constructed in these studies were "~5.0 kb in length, and could thus be successfully packaged into mature virions to generate vTKp-globin-c~, vSV40p-globin-ot, and voq~-globin-ot recombinant AAV virions, respectively (Fig. 1) . Since the recombinant viral genomes also contained a neo R selectable-marker gene, upon infection of K562 cells with these virions, G418-resistant cell populations could be readily obtained. These donal cell populations for each recombinant virus were pooled and their genomic DNA was analyzed on Southern blots as described under Materials and Methods. A representative Southern blot probed with a neo-speciiic DNA probe is shown in Fig. 2 .
As is evident, none of the DNA samples isolated from mockinfected K562 cells contained specific neo-hybridizing bands. However, in DNA samples isolated from each of the recombinant virus-infected cell populations, the probe detected several distinct hybridizing fragments suggesting stable integration of the recombinant viral genomes into the chromosomal DNA. Similar results were obtained when an o~-globin-specific DNA was used as a probe except for detection of the endogenous alleles (data not shown).
Expression Analysis of the Endogenous cr-globin Gen~ It was
next of interest to determine whether the transduced antisense c~-globin sequences modulated the levels of expression of the constitutively expressed c~-globin gene in K562 cells. Total KNA samples isolated from mock-infected, or the recom' binant virus-infected cells were analyzed on Northern blots as described under Materials and Methods. Such a blot is depicted in Fig. 3 . It is evident that when a neo-spedfic DNA was used as probe (Fig. 3 A) , no hybridization was detected in mock-infected K562 cells (Fig. 3, lane 1) , whereas the probe detected specific RNA transcripts in the three recombinant virus-infected cultures (Fig. 3, lanes 2-4) . The sizes of the transcripts correspond to their respective genomes. When the same blot was probed with an ot-globin probe (Fig. 3 B) , mock-infected (Fig. 3, lane I) as well as vTKp-globin-o~ virus-infected (Fig.  3, lane 2) K562 showed abundant expression of the endogenous ol-globin gene. However, cell populations transduced with vSV4Op-globin-c~ (Fig. 3, lane 3) and voq>-globin-c~ (Fig.  3, lane 4) virions showed a dear suppression of expression of the endogenous gene. Densitometric analyses of the hybridization signals revealed the extent of this suppression to be "~29% with vSV4Op-globin-ot, and •91% with vo~p-globin-o~ recombinant virions with reference to the levels of /3-actin mRNA (Fig. 3 C) . These levels also corresponded well with ethidium bromide-induced fluorescence intensities of 28s and 18s ribosomal RNA bands in these cell populations (Fig. 3 D) . We also noted that expression of the neospecific KNA transcripts was significantly lower with the TK promoter than with the SV40 promoter (Fig. 3 A) indicating the relative inefficiency of the TK promoter function compared with that of the SV40 promoter in K562 cells.
These data suggest that it may indeed be feasible to employ the AAV-based antisense vectors to modulate the expression of the constitutively over-expressed c~-globin gene in human hematopoietic cells.
D i~u m o n
The potential application of the AAV-based vector system for the purpose of gene therapy in humans is gaining attention (8) (9) (10) (11) (12) (13) . That the AAV-based vectors may prove to be a useful alternative to the more commonly used retrovirusbased vectors, stems from the fact that AAV is a nonpathogenic virus whereas retroviruses are intimately associated with neoplastic events (27) . AAV has thus far not been shown to be associated with any malignant disease (28) , and interestingly, AAV has been shown to possess anti-oncogenic properties both in vitro and in vivo (29) (30) (31) (32) .
Of the several human diseases amenable to genetic correction, those affecting the hematopoietic system appear to be potential candidates for gene therapy. In the case of B-thalassemia, which is characterized by the defective B-glohin production, a mechanism to deliver a functional B-globin gene would be a preferred form of treatment. Indeed, in our recent studies with the recombinant AAV vector system, we have documented successful transduction and erythroid cellspecific expression of a normal human B-globin gene in human hematopoietic cells in vitro (32a). It is also noteworthy that Walsh et al. (8) have recently described the construction of, and in vitro expression from, a recombinant AAV-q,-globin vector.
A second line of therapeutic measure that could ameliorate the severity of this disease would be to suppress the accumulation of excessive levels of the c~-globin chains in red blood cells which leads to their premature destruction. The antisense strategy that we employed in our present studies might prove as a useful mode of treatment for such a defect. The extent of suppression was highest with the c~-globin gene promoter-driven antisense sequences. This probably suggests the maximal efficiency of a natural promoter in transcriptional activation by tmns-acting factors compared with the heterologous promoters. The mechanism of antisense RNA inhibiting the expression of a target gene is not clearly understood. Yet, in principle, the antisense RNA could act at the following levd(s): transcription, mRNA processing, transport out of the nucleus, translation, and/or general stability of the mRNA (33) . A cogent example of near-total suppression in vitro of HIV-1 replication mediated by an antisense AAV vector has recently been provided by Chatterjee et al. (9) . In our studies, no attempts were made to control the levels of antisense RNA production, but we presume that most of the antisense RNA transcripts that were generated were utilized in hybridization with the complementary target c~-globin mKNA. Using strand-specific RNA probes, we could not detect any significantly free antisense transcripts in K562 ceils transduced with the recombinant AAV virions, yet abundant expression of these transcripts was evident in transduced HeLa cells as determined by Northern blot analysis (data not shown).
Although we were able to achieve high-level suppression of expression of the endogenous c~-globin gene in clonal populations of relatively homogeneous K562 cells, it may be undesirable to completely block the expression of the required basal amounts of the endogenous c~-globin gene in primary human hematopoietic cells by over-producing the antisense cr RNA transcripts. However, given the heterogeneous nature of the primary human hematopoietic cells, we believe this unlikdy to be the case. Whether this strategy with primary cultures will prove to be effective in vitro remains to be determined. It also remains to be ascertained whether this treatment modality will be safe and efficacious in an animal model in vivo, before its potential use in human gene therapy. This form of gene transfer using antisense RNA production may also prove to be useful in a wide variety of disease conditions that are characterized by undesirable over-expression of endogenous genes as well as that from infectious agents.
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